NasdaqGS - Nasdaq Real Time Price ? USD Incyte Corporation (INCY) Follow Compare 71.72 +1.33 (+1.89%) At close: 4:00 PM EST 71.72 0.00 (0.00%) After hours: 4:45 PM EST All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations Goldman Sachs: Incyte Corporation (INCY) Is A Top Growth Investor Stock We recently made a list of Goldman Sachs’ Top Growth Investors: 34 Stocks With The Highest Investment For Growth. In this piece, we will look at where Incyte Corporation (NASDAQ:INCY) ranks on the list. With the 2024 US Presidential Election having come to a close, Wall Street can now focus on the future of artificial […] Insider Monkey ? 11 hours ago INCY +1.89% Biotech Stock Roundup: SAGE, INCY Suffer Setbacks, JAZZ Wins Oncology Drug Approval & More SAGE and INCY suffer setbacks due to the failure of HD and CSU studies, respectively. Zacks ? yesterday INCY +1.89% SAGE Equities Close Mostly Higher as Nvidia Jumps Ahead of Earnings; Wall Street Tracking Russia-Ukraine Conflict Equities Close Mostly Higher as Nvidia Jumps Ahead of Earnings; Wall Street Tracking Russia-Ukraine Conflict PREMIUM MT Newswires ? 3 days ago NVDA ^GSPC COMP Equity Markets Close Mixed Ahead of Nvidia Earnings Equity Markets Close Mixed Ahead of Nvidia Earnings PREMIUM MT Newswires ? 3 days ago NVDA ^GSPC COMP S&P 500 Gains and Losses Today: Supermicro Roars Back After Compliance Filing The S&P 500 added 0.4% on Tuesday, Nov. 19, as investors digested a strong report from a major retailer and awaited more big-name earnings results. Investopedia ? 3 days ago ^GSPC SMCI INCY +1.89% Sector Update: Health Care Stocks Decline Sector Update: Health Care Stocks Decline PREMIUM MT Newswires ? 3 days ago INSM NVO INCY +1.89% Incyte Collapses. Why Its $750 Million Escient Acquisition Now Looks Shattered. Incyte stock tumbled Tuesday after the company scrapped one drug and paused enrollment in the study of another. Investor's Business Daily ? 3 days ago INCY +1.89% Top Midday Decliners Top Midday Decliners PREMIUM MT Newswires ? 3 days ago GDHG INCY +1.89% Equities Mixed Intraday Amid Growing Russia-Ukraine Conflict Equities Mixed Intraday Amid Growing Russia-Ukraine Conflict PREMIUM MT Newswires ? 3 days ago ^GSPC COMP INCY +1.89% Incyte Pauses Enrollment in Chronic Spontaneous Urticaria Study INCY stops enrollment in the phase II study of MRGPRX2 in CSU after making certain in vivo preclinical toxicology discoveries. Zacks ? 3 days ago INCY +1.89% Incyte Stock Slumps After Firm Scraps Drug, Pauses Enrollment in Other Study Incyte led S&P 500 decliners Tuesday afternoon after the pharmaceutical firm said it will stop developing one drug and pause enrollment in the study of another. Investopedia ? 3 days ago INCY +1.89% ^GSPC Incyte Is the S&P 500’s Worst Performer Today. What’s Hitting the Stock. Shares of Incyte were spiraling lower Tuesday after the biopharmaceutical company provided negative updates on two research studies. Incyte stock plummeted 1?4% to $66?.36 in Tuesday trading, on track for its largest daily percentage decrease since 2018, according to Dow Jones Market Data. The company said that two Phase 2 studies hit roadblocks, including one involving MRGPRX2 (INCB000262), a treatment for a range of inflammatory disorders. Barrons.com ? 3 days ago INCY +1.89% Incyte's $750 Million Escient Deal Faces Setback With Toxicology Issues In Two Investigational Drugs, Analyst Flags Challenges On Monday, Incyte Corporation (NASDAQ:INCY) announced that it will pause enrollment in the ongoing Phase 2 study of MRGPRX2 (INCB000262) in chronic spontaneous urticaria (CSU). The decision was made following the observation of certain in vivo preclinical toxicology findings. These data have been shared with the FDA, and Incyte will work closely with the FDA to determine the next steps. Also Read: Incyte’s Jakafi Demand Is Strong, Analyst Upgrades Stock Enrollment in the other INCB000262 proof-o Benzinga ? 3 days ago INCY +1.89% Incyte Faces Challenges but Remains Focused on Strategic Growth Incyte Corporation Faces Pipeline Challenges Amid Stock Volatility GuruFocus.com ? 3 days ago INCY +1.89% Incyte sinks on setback for drugs acquired in $750M buyout The company paused testing of one candidate acquired in its April deal for Escient and scrapped another in a blow to its diversification plans. BioPharma Dive ? 3 days ago INCY +1.89% Incyte Provides Update on Early Phase MRGPRX2 and MRGPRX4 Programs WILMINGTON, Del., November 18, 2024--Incyte Provides Update on Early Phase MRGPRX2 and MRGPRX4 Programs Business Wire ? 4 days ago INCY +1.89% Is Incyt Corporation (INCY) the Best Immunotherapy Stock to Buy Now? We recently compiled a list of the 10 Best Immunotherapy Stocks to Buy Now. In this article, we are going to take a look at where Incyt Corporation (NASDAQ:INCY) stands against the other immunotherapy stocks. The global immunotherapy drugs market is rapidly expanding, with projections to grow from $240 billion in 2023 to $1.3 trillion by […] Insider Monkey ? 4 days ago INCY +1.89% Here’s How Jakafi’s Patent Expiry Impacts Incyte Corporation’s (INCY) Growth Prospects Many investors continue to be worried about Incyte’s financial prospects when the patent for the company’s blood cancer medication, Jakafi, expires in 2028. We believe the company is preparing well for the post-expiry period and is on a growth path irrespective of the financial impact of patent expiry. Incyte Corporation (INCY) is a biopharmaceutical company […] Insider Monkey ? 6 days ago INCY +1.89% Incyte to Present at Upcoming Investor Conference WILMINGTON, Del., November 14, 2024--Incyte (Nasdaq: INCY) announced today that it will present at Citi’s 2024 Global Healthcare Conference on Tuesday, December 3, 2024 at 3:15 p.m. in Miami. Business Wire ? 8 days ago INCY +1.89% Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) WILMINGTON, Del., November 07, 2024--Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire ? 15 days ago INCY +1.89% Performance Overview Trailing total returns as of 11/22/2024, which may include dividends or other distributions. Benchmark is S&P 500 Return INCY S&P 500 YTD +14.22% +25.15% 1-Year +34.74% +31.54% 3-Year +11.18% +27.06%
